|
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Korean J Intern Med. 2023;38(4):578-578. Published online June 9, 2023
|
|
|
Hemato-oncology
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma
[corrected-article]
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Korean J Intern Med. 2023;38(2):238-247. Published online January 26, 2023
Background/Aims: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for pre..
|
|
|
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
Young Hoon Park, Dae-Young Kim, Yeung-Chul Mun, Eun Kyung Cho, Jae Hoon Lee, Deog-Yeon Jo, Inho Kim, Sung-Soo Yoon, Seon Yang Park, Byoungkook Kim, Soo-Mee Bang, Hawk Kim, Young Joo Min, Jae Hoo Park, Jong Jin Seo, Hyung Nam Moon, Moon Hee Lee, Chul Soo Kim, Won Sik Lee, So Young Chong, Doyeun Oh, Dae Young Zang, Kyung Hee Lee, Myung Soo Hyun, Heung Sik Kim, Sung-Hyun Kim, Hyukchan Kwon, Hyo Jin Kim, Kyung Tae Park, Sung Hwa Bae, Hun Mo Ryoo, Jung Hye Choi, Myung-Ju Ahn, Hwi-Joong Yoon, Sung-Hyun Nam, Bong-Seog Kim, Chu-Myong Seong
Korean J Intern Med. 2022;37(4):841-850. Published online June 28, 2022
Background/Aims: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL).
Methods: We included 87 patients with newly diagnosed acute myeloid l..
|
|
|
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Hemato-oncology
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
Sang Kyun Sohn, Joon Ho Moon, In Hee Lee, Jae Sook Ahn, Hyeoung Joon Kim, Joo Seop Chung, Ho Jin Shin, Sung Woo Park, Won Sik Lee, Sang Min Lee, Hawk Kim, Ho Sup Lee, Yang Soo Kim, Yoon Young Cho, Sung Hwa Bae, Ji Hyun Lee, Sung Hyun Kim, Ik Chan Song, Ji Hyun Kwon, Yoo Jin Lee
Korean J Intern Med. 2018;33(6):1194-1202. Published online December 15, 2017
Background/Aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System.
Methods: A total of 279 H/VH risk MD..
|
|
|
Primary Retroperitoneal Mucinous Cystadenocarcinoma: A Case Report and Review of the Literature
Sun Ah Lee, Sung Hwa Bae, Hun Mo Ryoo, Hyun Young Jung, Saet Byul Jang, Yoon Seup Kum
Korean J Intern Med. 2007;22(4):287-291. Published online December 20, 2007
Primary retroperitoneal mucinous cystadenocarcinoma is a rare tumor. Only about 30 such cases have been reported in the worldwide literature, and a few Korean cases have been reported. The pathogenesis is not clear, and coelomic metaplasia of the retroperitoneal mesothelium has gained wide suppor..
|
|
|
The Efficacy of Paclitaxel and Cisplatin Combination Chemotherapy for the Treatment of Metastatic or Recurrent Gastric Cancer: a Multicenter Phase II Study
Sang Joon Shin, Sung Ho Chun, Kyeong Ok Kim, Min Kyoung Kim, Kyung Hee Lee, Myung Soo Hyun, Sung Hwa Bae, Hun Mo Ryoo, Young Rok Do, Ki Young Kwon, Hong Suk Song
Korean J Intern Med. 2005;20(2):135-140. Published online June 30, 2005
BackgroundAlthough many treatments for advanced gastric cancer have been developed, only poor treatment results have generally been obtained. We performed a prospective study on the combination chemotherapy of paclitaxel and cisplatin (PC). The primary objectives of the study ..
|
|
|
